Two experts discuss the evolving treatment landscape for patients with non-small cell lung cancer (NSCLC) and reviews the role of molecular testing and discusses some of the challenges faced.
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More